A Phase II Randomized Study of Ibrutinib and Rituximab With or Without Venetoclax in Previously Untreated Waldenstrm's Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL)
Study of Venetoclax in Addition to Usual Treatment for Patients with Waldenstrm's Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL)
Sponsor: NIH
Enrolling: Male and Female Patients
IRB Number: AAAT9405
U.S. Govt. ID: NCT04840602
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: The purpose of this study is to compare the usual treatment alone to using venetoclax plus the usual treatment. The addition of venetoclax to the usual treatment could shrink the cancer. But, it could also cause side effects. This study will help the study doctors find out if this different approach is better than the usual approach. To decide if it is better, the study doctors will be looking to see if the drug combination of venetoclax with ibrutinib and rituximab shrinks and prevents the return of Waldenstrm's Macroglobulinemia/Lymphoplasmacytic Lymphoma compared to the usual approach.
Divaya Bhutani, MD
Do You Qualify?
Are you at least 18 years old? Yes No
Have you been diagnosed with Waldenstrms macroglobulinemia (WM) or Lymphoplasmacytic Lymphoma (LPL)? Yes No
Are you able to make regularly scheduled visits to the clinic for treatment and examinations? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Research Nurse Navigator